Overview

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Status:
Not yet recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) in adult patients with B cell malignancies after failure of autologous chimeric antigen receptor T- cell(CAR-T) therapy in china.

Phase:

Phase 1

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Fundamenta Therapeutics, Ltd.

Treatments:

Cyclophosphamide
Fludarabine